RDY logo

DR. REDDY'S LABORATORIES-ADR

RDYNYSE
Earnings Jan 19US Equity
$14.11β–Ό $0.04 (βˆ’0.28%)
Market closed Β· at close
πŸ””
Track RDY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.3%
7dβ–² 7.0%
14dβ–² 8.0%
30dβ–² 11.8%
ytdβ–² 0.5%
1yβ–² 5.0%
🏦Market Cap
$11.75B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
-3.5%
Declining
πŸ“ŠGross Margin
61.1%
High
πŸ’΅FCF Margin
5.5%
Moderate
βš–οΈP/S Ratio
3.4x
Fair
Otter Score
76
Strong

Trading Snapshot

Day Range
$14.10 – $14.33
52-Week Range
β€”
Volume (shares)
2,003,052
Avg Volume (shares)
β€”
Shares Outstanding
833.1M
Next Earnings
2027-01-19

Fundamentals Snapshot

Annual Revenue
$353.47B
Last Q Revenue
$86.59B
P/E Ratio
39.8
P/S Ratio
3.4x
EPS (TTM)
β€”
Dividend Yield
0.60%
Dilution (1yr)
+0.0%
RDY logo

DR. REDDY'S LABORATORIES-ADR

RDY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$353.5Bβ–² +8.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
52.8%β–Ό βˆ’9.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$48.9Bβ–Ό βˆ’32.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$32.1Bβ–² +166.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
833.3Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$59.3Bβ–Ό βˆ’$10.2B YoY
StockOtter Β· stockotter.space

About DR. REDDY'S LABORATORIES-ADR

Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Hold
42 analysts
Strong Buy8
Buy11
Hold10
Sell11
Strong Sell2
Ratings as of Oct 2026

Latest News & Updates

Zacks Investment ResearchΒ·3d ago

RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

Dr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.

The Motley FoolΒ·4d ago

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Semaglutide supply reloading will begin by November 2026. Base business revenue grew double digits excluding North American Lenalidomide.

Seeking AlphaΒ·6d ago

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

MarketBeatΒ·6d ago

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories NYSE: RDY reported second-quarter FY2027 revenue of INR 8,671 crore, or $905 million, down 1.5% from a year earlier but up 7.4% sequentially, as lower North American lenalidomide sales offset gro

Defense WorldΒ·15d ago

Dr. Reddy’s Laboratories (NYSE:RDY) Shares Cross Above Two Hundred Day Moving Average – Time to Sell?

Dr. Reddy's Laboratories Ltd (NYSE: RDY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $12.92 and traded as high as $12.94

PRNewsWireΒ·Sep 24

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY).